Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland
19 Febrero 2024 - 5:15AM
Orion to investigate the possible outsourcing of its pharmaceutical
production in Kuopio, Finland
ORION CORPORATION PRESS RELEASE 19 FEBRUARY 2024 at 13:15 EET
Orion to
investigate the possible outsourcing of its
pharmaceutical production in Kuopio, Finland
Orion Corporation is evaluating the possible outsourcing
of its pharmaceutical production in Kuopio, part of its Global
Operations function, to an entity outside Finland. The basis for
the possible outsourcing would be the lack of competitiveness of
the Kuopio plant and the high investment needs of the
plant.
The evaluation is due to the low competitiveness of the plant,
low capacity utilisation, increasing quality requirements in the
pharmaceutical industry, and high investment needs. Volumes of the
plant are low and due to the lack of competitiveness, outlook for
growth is very limited. Therefore, the additional investment needed
would not be justified.
The products currently manufactured in Kuopio would continue to
be part of Orion’s product portfolio also in the future. The
estimated time scope is that the plant would continue to operate
until at least the summer of 2026.The company has today issued a
negotiation proposal in accordance with the Co-operation Act within
undertakings regarding the reorganisation of operations and
possible personnel reductions. The statutory negotiations include
the entire personnel in operations and functions which support
production in the Kuopio plant, altogether about 40 people. Other
employees working in the Kuopio plant are not impacted by the
statutory negotiations.
Orion’s manufacturing plant in Kuopio specialises in liquids and
self-care products. Among the most widely known of the products
manufactured in Kuopio are nasal sprays, cough medicines, and ear
drops.
Orion’s Global Operations and Quality Management have about
1,900 employees in total. Global Operations consists of
production at Orion's own plants in Espoo, Turku, Kuopio and Salo;
an external supplier network; procurement; and Fermion Oy, which
manufactures active pharmaceutical ingredients in Hanko and
Oulu. Contact
person:
Terhi Ormio, VP, CommunicationsOrion CorporationTel. +358 50 966
4646E-mail: terhi.ormio@orion.fiAbout Orion
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and consumer health products. The core therapy areas of
our pharmaceutical R&D are oncology and pain. Proprietary
products developed by Orion are used to treat cancer, neurological
diseases and respiratory diseases, among others. Orion's net sales
in 2023 amounted to EUR 1,190 million and the company had about
3,600 employees at the end of the year. Orion's A and B shares are
listed on Nasdaq Helsinki.
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandwww.orion.fi
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2023 a May 2024